The TRACTION trial was a pragmatic, multicenter, double-blind, cluster-randomized, placebo-controlled trial. It evaluated whether a hospital policy of routine tranexamic acid (TXA) use in patients undergoing major noncardiac surgeries would safely reduce the incidence of red cell transfusion.
A recent UK Patient Safety Alert has highlighted the potential for serious harm if the incorrect administration set is used for transfusion of blood or blood components.
Red cell transfusions are frequently required in patients with myelodysplastic syndromes (MDS), yet the overall cost of transfusion, extending beyond the unit price, is not well defined.
Investigators undertook an observational prospective study at Monash Medical Centre, a 640-bed tertiary-level university hospital in Melbourne, Australia.
The Australian and New Zealand Society of Blood Transfusion (ANZSBT) recently released a Position statement on prevention of transfusion-transmitted cytomegalovirus (TT-CMV).
The statement reflects the ANZSBT consensus informed by a systematic review, haemovigilance data, pre-clinical evidence, and review of international guidance
